Generalized Anxiety Disorder Epidemiology Forecast 2025-2034

Approximately 3% of the adult population is affected by generalized anxiety disorder (GAD), with childhood anxiety occurring in around 1 in 4 children between the ages of 13 and 18. The primary symptom of this mental health condition is excessive and persistent worry about everyday things.

Generalized Anxiety Disorder Epidemiology Forecast Report Coverage

The “Generalized Anxiety Disorder Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of generalized anxiety disorder. It projects the future incidence and prevalence rates of generalized anxiety disorder across various populations. The study covers age and type as major determinants of the generalized anxiety disorder-affected population. The report highlights patterns in the prevalence of generalized anxiety disorder over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of generalized anxiety disorder in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Generalized Anxiety Disorder: Disease Overview

Generalized anxiety disorder (GAD) refers to a mental health condition that is characterized by excessive worry and a constant feeling of being overwhelmed about everyday things. Most of the patients with this condition have one or more psychiatric disorders such as a certain phobia, social anxiety disorder, and panic disorder, among others. Symptoms of GAD are reported to fluctuate over time and generally worsen when the patient is undergoing stress.

Generalized Anxiety Disorder: Treatment Overview

Treatment for generalized anxiety disorder usually involves a combination of psychotherapy and medication. Mental health professionals commonly use cognitive behavioral therapy (CBT) to help patients unlearn negative thoughts and behaviors. Medications such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) antidepressants also help to manage the symptoms of generalized anxiety disorder.

Epidemiology

The generalized anxiety disorder epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for generalized anxiety disorder by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for generalized anxiety disorder and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• It is estimated that approximately 3% of the adult population has generalized anxiety disorder, with the condition usually beginning in childhood or adolescence.
• Around 1 in 4 children between the ages of 13 and 18 experience childhood anxiety at some point, with the average age of onset being 11.
• Research shows that generalized anxiety disorder frequently co-occurs with major depression, with women having twice the likelihood of being affected compared to men.
• As per a study published in the Middle East Current Psychiatry (2023), about 4.05% of the global population, or nearly 301 million people are affected by an anxiety disorder.

Country-wise Generalized Anxiety Disorder Epidemiology

The generalized anxiety disorder epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of generalized anxiety disorder varies significantly between countries due to differences in cultural attitudes toward mental health, healthcare access, and diagnostic practices. Socioeconomic factors, stressors, and levels of public awareness also influence prevalence rates in different regions. In the United States, about 3.1% of the population, or 6.8 million adults are affected by generalized anxiety disorder.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of generalized anxiety disorder based on several factors.
• Generalized Anxiety Disorder Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of generalized anxiety disorder are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of generalized anxiety disorder epidemiology in the 8 major markets?
• What will be the total number of patients with generalized anxiety disorder across the 8 major markets during the forecast period?
• What was the country-wise prevalence of generalized anxiety disorder in the 8 major markets in the historical period?
• Which country will have the highest number of generalized anxiety disorder patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of generalized anxiety disorder during the forecast period of 2025-2034?
• What are the currently available treatments for generalized anxiety disorder?
• What are the disease risks, signs, symptoms, and unmet needs of generalized anxiety disorder?

This product will be delivered within 3-5 business days.